Overcoming Limitations of Current Treatment Paradigms

Despite recent advancements, the current cancer treatment paradigm has failed to achieve durable responses in most cancers due to the development of treatment resistance, relapse and metastasis.

Our research suggests that activation of stress, common across a wide range of cancers and precision therapeutic classes, could result in the activation of responsive stress mitigating pathways and immune suppression in the tumor microenvironment.  As a result, cancer cells cope with the stress by altering their phenotype and reprogramming the tumor microenvironment to enable their survival in these stressful conditions, enabling them to achieve resistance and metastasis.

Our clinical-stage therapeutic candidates are designed to modulate these critical pathways and represent a novel approach for addressing treatment resistance, cancer relapse and metastasis.